ArticleBMC infectious diseases2025
Acute kidney injury of intravenous colistin sulfate compared with colistimethate sodium: a real-world, retrospective cohort study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The outcomes in nephrotoxicity among therapies utilizing three distinct polymyxins: a systematic review and network meta-analysis.Frontiers in medicine · 2026Pooled it
- Synergistic strategies to rescue the last-resort antibiotic colistin.Archives of microbiology · 2026Review
- The efficacy and safety of colistimethate sodium in the treatment of carbapenem-resistant Gram-negative bacilli: a real-world observational study.Frontiers in cellular and infection microbiology · 2026Observational
- Optimizing Colistin Sulfate Dosing in Severe Infections: A Population Pharmacokinetic Model-Guided Approach.Drug design, development and therapy · 2026Article
- Commentary: Efficacy, safety, and therapeutic drug monitoring of polymyxin B sulfate and colistin sulfate in critically ill patients: a real-world retrospective study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe nephrotoxicity associated with polymyxins is a critical safety concern in clinical practice. The aim of this study was to compare the nephrotoxicity of patients treated with colistin sulfate (CS) and colistin methanesulfonate (CMS).
methodsData on inpatients who received intravenous colistin (CS) or colistin methanesulfonate (CMS) for over 72 h were collected from January to December 2023. The primary outcome was the incidence of acute kidney injury (AKI) associated with polymyxins, while the secondary outcome was 30-day all-cause mortality. Furthermore, Cox proportional hazard regression analysis was used to identify the risk factors of polymyxin-induced AKI.
resultsA total of 291 patients were included in this study. The overall incidence of AKI was significantly higher in patients who received CMS compared to those who received CS in the unmatched cohort (29.70% vs. 7.37%) and in the propensity score matching (PSM) cohort (26.30% vs. 10.00%), respectively. However, 30-day all-cause mortality was significantly higher in the CS cohort than in the CMS cohort before (27.37% vs. 15.84%) and after (33.75% vs. 15.00%) PSM. CMS therapy and a lower baseline estimated glomerular filtration rate (eGFR) were identified as independent risk factors for polymyxin-induced AKI.
conclusionsThis was the first study to investigate the nephrotoxicity difference between CS and CMS to our best knowledge. In this study, the incidence rate of AKI was significantly lower in the CS cohort compared with the CMS cohort, however, 30-day all-cause mortality rate was significantly higher in the CS cohort than in the CMS cohort. Further validation of these findings requires more prospective multicentre studies with a large sample size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.